We are excited to announce the initiation of two clinical studies evaluating ST-067, our decoy-resistant IL-18, in hematologic cancers. The first study will assess ST-067 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and the second will evaluate ST-067 in combination with teclistamab (TECVAYLI®) in patients with relapsed/refractory multiple myeloma. These studies represent an important step forward in expanding the therapeutic potential of our platform and this upcoming week, we look forward to presenting preclinical data at the 2024 American Society of Hematology Annual Meeting demonstrating the therapeutic activity of ST-067 in hematologic malignancies . Read the full press release: https://lnkd.in/e__zWHsv #hematology #clinicaltrials #ASH24
Simcha Therapeutics
Biotechnology Research
New Haven, Connecticut 1,375 followers
Overcoming biological challenges in clinically translatable pathways.
About us
Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied in a Phase 1/2 clinical trial, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Beyond IL-18, the company’s underlying approach to immune-biology and cytokine engineering has broader potential to support disease-modifying therapeutic options for a range of significant diseases.
- Website
-
https://www.simchatx.com/
External link for Simcha Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- New Haven, Connecticut
- Type
- Privately Held
Locations
-
Primary
Get directions
New Haven, Connecticut , US
Employees at Simcha Therapeutics
Updates
-
We are honored to support our founder Aaron Ring as he fundraises and trains in the 2024 #TimmermanTraverse. Proceeds from the event will support Life Science Cares, Inc. and its mission to activate the financial and human capital of the life science industry and disrupt the cycle of poverty in our communities. Congratulations to all participants!
They’re HALFWAY! The 2024 #TimmermanTraverse team has reached the halfway point for their training and for their fundraising. A sincere thanks to all of the sponsors who have signed on already to support Life Science Cares' partnerships and programs, including our leading sponsors KCap Biotechnology Fund LP and HSBC Innovation Banking. Read more at https://lnkd.in/gCaT7Sz4.